Securities Code: 300122
Securities Abbreviation: Zhifei Biological
Announcement No.: 2026-44
Chongqing Zhifei Biological Products Co., Ltd.
Announcement on Acceptance of Clinical Trial Application for Nasal Spray Recombinant Respiratory Syncytial Virus Vaccine (Chimpanzee Adenovirus Vector)
The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from false or misleading statements or material omissions.
Chongqing Zhifei Biological Products Co., Ltd. (hereinafter referred to as the "Company") recently learned that the nasal spray recombinant respiratory syncytial virus vaccine (chimpanzee adenovirus vector) (hereinafter referred to as the "Nasal Spray Recombinant RSV Vaccine"), developed by its wholly-owned subsidiary Beijing Zhifei Green Bamboo Pharmaceutical Co., Ltd. (hereinafter referred to as "Zhifei Green Bamboo"), has received the acceptance notice for its drug clinical trial application from the National Medical Products Administration (Acceptance No.: CXSL2600844). Within 60 days from the date of acceptance, if no negative or questioning opinion is received from the drug review center, Zhifei Green Bamboo may proceed with the clinical trial according to the submitted plan.
I. Project Overview